<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04566185</url>
  </required_header>
  <id_info>
    <org_study_id>NIMAO/2018-03/LC-01</org_study_id>
    <nct_id>NCT04566185</nct_id>
  </id_info>
  <brief_title>Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma</brief_title>
  <acronym>EVA DOPA</acronym>
  <official_title>Evaluation of the Value of 18F-fluorodeoxyglucose Positron Emission Tomography (FDG PET) and Brain Perfusion Computed Tomography (CT Perfusion) for Predicting the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Patients With Recurrent Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this pilot study, the study evaluators will evaluate the ability of positron emission&#xD;
      tomography (PET) with 18F-fluorodeoxyglucose (FDG PET) and the computed tomography (CT)&#xD;
      perfusion scanner, individually and combined, to predict the effectiveness of anti-angiogenic&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Categorization of patients as responders or non-responders to treatment</measure>
    <time_frame>2 months</time_frame>
    <description>Measured by MRI according to Response Assessment in Neuro-Oncology (RANO) criteria: Complete response/Partial response/stable/progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic Tumor Volume</measure>
    <time_frame>Day 0</time_frame>
    <description>FDG PET</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic Tumor Volume</measure>
    <time_frame>Day 14</time_frame>
    <description>FDG PET</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fixation Index</measure>
    <time_frame>Day 0</time_frame>
    <description>Maximum standard uptake value (SUV) and average SUV of the lesion divided by maximum SUV and average SUV of the striata</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fixation Index</measure>
    <time_frame>Day 14</time_frame>
    <description>Maximum standard uptake value (SUV) and average SUV of the lesion divided by maximum SUV and average SUV of the striata</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>permeability-surface area product</measure>
    <time_frame>Day 0</time_frame>
    <description>CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>permeability-surface area product</measure>
    <time_frame>Day 14</time_frame>
    <description>CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebral blood flow</measure>
    <time_frame>Day 0</time_frame>
    <description>CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebral blood flow</measure>
    <time_frame>Day 14</time_frame>
    <description>CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalized permeability-surface area product to healthy brain</measure>
    <time_frame>Day 0</time_frame>
    <description>CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalized permeability-surface area product to healthy brain</measure>
    <time_frame>Day 14</time_frame>
    <description>CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalized cerebral blood flow to healthy brain</measure>
    <time_frame>Day 0</time_frame>
    <description>CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalized cerebral blood flow to healthy brain</measure>
    <time_frame>Day 14</time_frame>
    <description>CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter-rater reproducibility of FDG PET</measure>
    <time_frame>End of study (September 2022)</time_frame>
    <description>LIN intraclass correlation coefficient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter-rater reproducibility of CT scan</measure>
    <time_frame>End of study (September 2022)</time_frame>
    <description>LIN intraclass correlation coefficient</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Patients with recurrent glioblastoma</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FDG PET</intervention_name>
    <description>IV application of F Dopa, 2 MBq per Kg, with a scout view (angle of view 90 °, 120 kV, 30 mAs), then an X-ray scan is performed for the attenuation correction ( 120 kV - 5mAs - pitch 0.531 - thickness // increment: 3.75mm//3.27mm -QAC filter - DFOV 25).&#xD;
PET acquisition: static in 3D mode for 20 minutes, 8 minutes after the injection of 18 F Dopa, the axial field of view is 25, the matrix in 256 x 256. After OSEM reconstruction 6 iterations and 24 subsets, with correction of attenuation and diffusion, then Gaussian filter of frequency 4, 47 contiguous axial sections of 3.26 mm are obtained.</description>
    <arm_group_label>Patients with recurrent glioblastoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CT scan</intervention_name>
    <description>Localization propeller without injection: 120kV - mA regulation (Noise Index 15) - pitch 0.969 - thickness // increment: 5mm // 5mm - Soft filter - Asir 60% - DFOV 25.&#xD;
Acquisition begins 5 seconds after the start of the injection of 60 ml of contrast product (VISIPAQUE) at 4 cc / second without (acquisition characteristics: 80 kV - 100 mAs -- thickness: 5mm // 8 images / rotation - STD filter - Asir 50% display field of view (DFOV) 25 - phase1: 5s then phase2 15s).&#xD;
Diagnostic quality CT: 120kV - Regulation of mA (Noise Index 15) - pitch 0.531 - thickness // increment: 1.25 // 0.625mm - Soft filter - Asir 60% - DFOV 25.</description>
    <arm_group_label>Patients with recurrent glioblastoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Magnetic resonance imaging (MRI)</intervention_name>
    <description>If the examination is performed on the SIEMENS SKYRA 3T device: 32 channel head coil antenna, if on the PHILIPPS INGENIA 1.5 T device: DStream HeadSpine Coil antenna.&#xD;
The sequence begins with an axial, coronal and sagittal &quot;Survey&quot; topogram, lasting 1 minute.&#xD;
Then axial sequence T1, Axial T2 *, Axial cerebral perfusion (Injection of gadolinium (0.1 mmol / kg, 5 cc / second), coronal T2, Axial T2 Flair, Axial DWI b100, Axial 3D T1 gadolinium</description>
    <arm_group_label>Patients with recurrent glioblastoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of patients with recurrent glioblastoma for whom the&#xD;
        initiation of treatment with Bevacizumab is decided by the Neuro-oncology mulitdisciplinary&#xD;
        committee at the Nîmes University Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must have given their free and informed consent and signed the consent&#xD;
             form&#xD;
&#xD;
          -  The patient must be a member or beneficiary of a health insurance plan&#xD;
&#xD;
          -  The patient has an WHO score ≤ 3&#xD;
&#xD;
          -  The patient's estimated life expectancy is more than 3 months.&#xD;
&#xD;
          -  Patient with histologically proven diagnosis of glioblastoma.&#xD;
&#xD;
          -  Patient presenting with tumor progression on morphological MRI confirmed by a&#xD;
             multidisciplinary committee.&#xD;
&#xD;
          -  Patient with a unilateral supratentorial target lesion upon inclusion to establish a&#xD;
             tumor region of interest (ROI) zone and an equivalent ROI zone in contralateral&#xD;
             healthy tissue.&#xD;
&#xD;
          -  Patient progressing after radiotherapy and at least one line of chemotherapy with&#xD;
             TEMODAL&#xD;
&#xD;
          -  Patient in whom treatment with Bevacizumab monotherapy has been validated by a&#xD;
             multidisciplinary committee.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject is participating in an interventional study, or is in a period of&#xD;
             exclusion determined by a previous study&#xD;
&#xD;
          -  The subject refuses to sign the consent&#xD;
&#xD;
          -  It is impossible to give the subject informed information&#xD;
&#xD;
          -  The patient is under safeguard of justice or state guardianship&#xD;
&#xD;
          -  Pregnant or breast feeding patients&#xD;
&#xD;
          -  Hypersensitivity to iodinated contrast media and creatinine clearance less than 60 ml&#xD;
             / minute.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Laurent Collombier</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nimes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurent Collombier</last_name>
    <phone>04.66.68.32.49</phone>
    <email>laurent.collombier@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>04.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent Collombier</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Chambert</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melanie Sainmont</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent Boudousq</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Olivier Kotzki</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Sébastien Guillamo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Thouvenot</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Le Floch</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Sophie Pruvot-Occean</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>September 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2020</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

